Exelixis News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

14.07.17	Company Spotlight: Exelixis (RTTNews)
21.06.17	Biopharma Stock Breakouts With Significant Developments and Market Activity (PR Newswire)
21.06.17	Biopharma Stock Breakouts With Significant Developments and Market Activity (PR Newswire)
20.06.17	AMGN's Xgeva To Face FDA In Feb, Double Treat For LPCN, SGEN Drops Cascade (RTTNews)
02.05.17	Investors: Covered Call reports for Exelixis, Facebook, Priceline, Pfizer Inc. and AT&T include trade ideas that offer returns of 18% or more! (PR Newswire)
14.03.17	Biotech Stocks Under Scanner -- Gilead Sciences, Exelixis, Mast Therapeutics, and Novavax (PR Newswire)
09.03.17	Beat market volatility with these stock option trade ideas for Citigroup, Exelixis, Gilead Sciences, Tesla Motors, and US Oil Fund! (PR Newswire)
27.02.17	New Cancer Therapeutics Drive the Cancer Biological Therapy Market (PR Newswire)
01.02.17	Activision Blizzard, Exelixis, Hanesbrands Inc., Altria Group Incorporated, Vale, and more offer option-trading opportunities that offer returns of more than 18% (PR Newswire)
31.01.17	AEZS Inches Closer To D-Day, EYEG Catches Investors' Eyes, MCRB On Watch (RTTNews)
12.01.17	Investors: Covered-Call Reports for BB&T Corporation, Exelixis, Merck & Company Incorporated, Parsley Energy Inc and Workday (PR Newswire)
09.01.17	Genentech Withdraws Counterclaim Against Exelixis In JAMS Arbitration (RTTNews)
05.01.17	Biotech Stocks Under Review -- Novavax, Gilead Sciences, ARIAD Pharma, and Exelixis (PR Newswire)
05.12.16	Covered Call reports for Exelixis, Alibaba, Procter & Gamble, Whiting Petroleum and GW Pharmaceuticals include trade ideas that offer returns of 20% or more! (PR Newswire)
22.11.16	InvestorsObserver releases covered-call reports for Exelixis, Valeant Pharmaceuticals, Cheniere Energy, General Electric and The Kroger Co (PR Newswire)
21.11.16	Biotech Stocks Under Review -- Novavax, Gilead Sciences, Ariad Pharma, and Exelixis (PR Newswire)
07.09.16	CERC Data Due Dec., SAMURAI Brings Cheer To CLCD, TNXP Slumps As Study Fails (RTTNews)
25.07.16	D-Day For TBRA, Nicox Falls As FDA Rejects Vesneo, EXEL Awaits EMA Decision (RTTNews)
24.05.16	EXEL Rises On Trial Data, XNPT Agrees To Be Acquired, NVO Faces FDA Panel Today (RTTNews)
26.04.16	AZN Breathes Easy, EXEL Scores FDA Nod, SRPT Disappointed, PETX On The Rise (RTTNews)
29.01.16	Data Due Mid Year For CORT, New Addition To HCV Armory, EXEL Gets FDA Date (RTTNews)
05.01.16	EXEL Shines On Meteor Impact, GILD Gets FDA Date, VCEL Moving Ahead (RTTNews)
27.11.15	AMGN In The Race For Humira Biosimilar, EXEL On Watch, IPXL Gets EC Nod (RTTNews)
11.11.15	FDA Okays Genentech's Cotellic In Combination With Zelboraf In Advanced Melanoma (RTTNews)
06.10.15	Exelixis Announces Positive Overall Survival Results From CoBRIM - Quick Facts (RTTNews)
25.08.15	GALE Climbs On IDMC's Guidance, NAVB Seeks Dual Listing, OCAT Gets Funds (RTTNews)
11.08.15	Exelixis Q2 Loss Narrows - Quick Facts (RTTNews)
22.07.15	Exelixis Plans 20 Mln. Stock Offering (RTTNews)
21.07.15	BMRN Expands Breast Cancer Trial, EXEL's Meteor Shines, HZNP Widens Horizons (RTTNews)
20.07.15	Pre-market Movers For July 20 (MS, HAS, EXEL, HAL, VSLR, LMT, UTX, CALM) (RTTNews)
20.07.15	Exelixis Records Modest Progression-free Survival In Phase 3 METEOR Trial (RTTNews)
01.07.15	Exelixis: FDA Extends PDUFA Action Date For Review Of NDA For Cobimetinib (RTTNews)
31.05.15	Exelixis: Phase 2 Trial Of Cabozantinib Meets Primary Endpoint (RTTNews)
01.05.15	MDCO Gets FDA Nod For 2 Products, EXEL Awaits METEOR Data, WX To Make History (RTTNews)
10.04.15	Medicines Tastes Bitter, EXEL Excels, ORPN Has A Blast, FWP For The Long Haul (RTTNews)
19.02.15	Exelixis: FDA Accepts For Review Genentech NDA For Cobimetinib With Vemurafenib (RTTNews)
07.01.15	Exelixis, Sobi Extend & Restructure Distribution Agreement For COMETRIQ (RTTNews)
15.12.14	Genentech Submits NDA For Cobimetinib With Zelboraf To Treat Advanced Melanoma (RTTNews)
02.12.14	FDA Lifts Hold On FLXN Study, All's Well With CPXX Trial, COMET Woes For EXEL (RTTNews)
01.12.14	Exelixis: COMET-2 Trial Of Cabozantinib Fails To Meet Primary Endpoint (RTTNews)
29.09.14	Exelixis Reports Positive Results From Phase 3 Trial Of Cobimetinib (RTTNews)
26.03.14	ACT Gets It Right, CPRX On The Move, HALO Shines, Keep Watch On GALT, INSM (RTTNews)
25.03.14	Exelixis Gets Approval For Cometriq In European Union For Treatment Of MTC (RTTNews)
20.02.14	Exelixis Q4 Loss Widens - Quick Facts (RTTNews)
23.01.14	Exelixis Prices $80 Mln Overnight Stock Offering (RTTNews)
25.09.13	Drug Approvals, Data Presentations, Conferences, Increased Funding, and Merger Agreements - Research Report on Theravance, Arena, Exelixis, Verenium, and Enanta (PR Newswire)
11.09.13	FOLD Cuts A Deal, SNTA On Watch, NanoString Makes Mega Leap, GALT Vaults (RTTNews)
10.09.13	Exelixis Begins Phase 3 Trial Of Cabozantinib In Patients With Advanced HCC (RTTNews)
12.08.13	Public Offerings of Common Stock, Financial Results, and Significant Progress in Key Development Programs - Research Report on BioCryst, Exelixis, Idenix, Puma Biotechnology, and Halozyme (PR Newswire)
06.08.13	Exelixis Q2 Loss Widens (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	295.60	0.96 %	K V
Lonza Grp	531.00	0.53 %	K V
Alcon	76.02	0.34 %	K V
Roche Hldg G	247.40	0.28 %	K V
ABB	48.86	0.27 %	K V
Swisscom	498.40	-0.62 %	K V
UBS Group	26.71	-0.67 %	K V
Zurich Insur Gr	533.00	-0.97 %	K V
Holcim	86.10	-1.01 %	K V
Sika	213.20	-2.47 %	K V

mehr

30.10.24		Anleger in New York halten sich zurück: NASDAQ Composite gibt zum Handelsende nach
30.10.24		Handel in New York: NASDAQ Composite verbucht Verluste
30.10.24		Gute Stimmung in New York: NASDAQ Composite mittags fester
30.10.24		Mittwochshandel in New York: NASDAQ Composite beginnt Mittwochssitzung in der Gewinnzone
15.10.24		Schwacher Handel in New York: NASDAQ Composite legt schlussendlich den Rückwärtsgang ein
15.10.24		Schwacher Handel: NASDAQ Composite zeigt sich leichter
15.10.24		Dienstagshandel in New York: NASDAQ Composite gibt nach
18.09.24		Angespannte Stimmung in New York: NASDAQ Composite präsentiert sich mittags schwächer

30.10.24

Anleger in New York halten sich zurück: NASDAQ Composite gibt zum Handelsende nach

30.10.24

Handel in New York: NASDAQ Composite verbucht Verluste

30.10.24

Gute Stimmung in New York: NASDAQ Composite mittags fester

30.10.24

Mittwochshandel in New York: NASDAQ Composite beginnt Mittwochssitzung in der Gewinnzone

15.10.24

Schwacher Handel in New York: NASDAQ Composite legt schlussendlich den Rückwärtsgang ein

15.10.24

Schwacher Handel: NASDAQ Composite zeigt sich leichter